Immunomedics makes $10 million placement

Article

Monoclonal antibody imaging agent developer Immunomedics of MorrisPlains, NJ, announced last week that it has sold $10 million inconvertible preferred stock to international investors. The investorscan convert the stock into shares of common stock over

Monoclonal antibody imaging agent developer Immunomedics of Morris

Plains, NJ, announced last week that it has sold $10 million in

convertible preferred stock to international investors. The investors

can convert the stock into shares of common stock over the next

two years.

Related Content
© 2025 MJH Life Sciences

All rights reserved.